newsfilter
← Latest News
GlobeNewswire·

Ryoncil® Profits Underpinning Substantial Growth Pipeline

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational